Pfizer pledges to strengthen lifelong health strategies for Asia-Pacific region
18 March 2012 | By Pfizer
Experts on ageing highlight importance of health as driver of economic growth...
List view / Grid view
18 March 2012 | By Pfizer
Experts on ageing highlight importance of health as driver of economic growth...
12 March 2012 | By Pfizer
Data from a Phase 3 study of Prevnar 13® met all study endpoints...
12 March 2012 | By Pfizer
Biocon and Pfizer have announced the conclusion of their alliance...
29 February 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for Eliquis® (apixaban)...
27 February 2012 | By Pfizer
Maker of Emergen-C®, #1 U.S. Vitamin C brand, expands Pfizer’s vitamin and dietary supplement business...
22 February 2012 | By Pfizer
Pfizer believes Prevnar 13 should be recommended for all adults 50 years of age and older...
17 February 2012 | By Pfizer
The framework agreement builds upon the MOU, and is an important milestone in the formation of a joint venture between the two companies...
15 February 2012 | By Pfizer
A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)...
30 January 2012 | By
Partners pledge innovative, coordinated action aimed at new WHO goals...
27 January 2012 | By Pfizer
The U.S. FDA has accepted its NDA for standard review of bosutinib...
27 January 2012 | By Pfizer
First treatment to demonstrate superior benefit in a Phase 3 study compared with another targeted agent in advanced RCC...
17 January 2012 | By Pfizer
Dimebon did not meet primary efficacy endpoints...
9 January 2012 | By Citigate Dewe Rogerson
SFJ announced that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial...
30 December 2011 | By Pfizer
First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia...
19 December 2011 | By Pfizer
Patients with Restless Legs Syndrome (RLS) show significant benefit...